Skip to main content
TipRanks
Go Ultimate75% OFF

Agenus (AGEN) Stock Price & Analysis

0 Followers

AGEN Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 239.28M
Enterprise Value
CHF 1.01B
Total Cash (Recent Filing)
CHF 66.94M
Total Debt (Recent Filing)
CHF 39.46M
Price to Earnings (P/E)
8.6
Beta
N/A
Next Earnings
Mar 16, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improving Revenue And Margins

The latest results show substantial improvement in revenue and reported profitability, indicating stronger contribution from collaborations, licensing, or services. If Agenus can sustain this performance, higher margins could support reinvestment in its pipeline and reduce dependence on external financing over the next several quarters.

Clinical Durability Signal

Durable responses in heavily pretreated metastatic colorectal cancer provide meaningful clinical validation for Agenus’s immuno-oncology approach. Although the evidence remains from an early-stage study, persistence of benefit could strengthen partnering prospects and support future development of the BOT+BAL franchise.

Lower Absolute Debt

The sharp reduction in reported debt improves the company’s absolute debt burden compared with the prior year and may reduce near-term repayment pressure. This gives management more flexibility to allocate resources toward clinical development, although the benefit is tempered by thin equity and continuing cash consumption.

Bears Say

Persistent Cash Burn

Agenus remains far from self-funding, with operating and free cash flow materially negative after a multi-year pattern of burn. Continued development spending without sustained product revenue or substantial partnership economics increases reliance on financing and could constrain the pace of pipeline investment.

Fragile Balance Sheet

Very thin equity leaves Agenus with limited financial cushion if operating results weaken, while the elevated debt-to-equity ratio magnifies balance-sheet sensitivity. This combination can restrict strategic flexibility and make future capital needs more consequential for shareholders and creditors.

Financing And Dilution Pressure

The amended loan preserves access to financing but carries a high interest rate and uses equity for part of the extension fee. That structure raises ongoing funding costs and creates potential dilution, reinforcing the challenge of financing operations while cash generation remains negative.

Agenus News

AGEN FAQ

What is Agenus’s market cap?
Agenus’s market cap is CHF239.28M.
When is Agenus’s upcoming earnings report date?
Agenus’s next earnings report is estimated for Mar 16, 2027 (not yet confirmed), which is in 118 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Nov 05, 2026. The company reported CHF0.017 earnings per share for the quarter, beating the consensus estimate of -CHF0.236 by CHF0.252.
Is Agenus overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -0.14.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of CHF0.017 in its last earnings report, beating expectations of -CHF0.236. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Agenus?
Hedge funds hold Agenus shares: the largest hedge-fund position in Agenus is 146,397,123 shares, and hedge funds decreased their holdings by 18.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology